Introduction
============

Cervical cancer remains the number one cause of mortality due to malignant neoplasm among 20 to 40-year-old women in Latin America, and the third most common cause of cancer death in females, second only to breast cancer and lung cancer.

In a recent study, the World Health Organisation (WHO) admitted that as many as 529,409 women worldwide will be diagnosed with cervical cancer, and 274,883 will die from the disease. No less than 80% of this burden is borne in less developed countries \[[@ref1]\].

In America, it is estimated that there are around 92,136 cases and 37,640 deaths per year, representing a significant economic loss, projected at being potentially greater than US\$ 3,6 billion \[[@ref2]\].

This is a pathology that has been recognised for more than 50 years as being a disease linked to the sexual habits of women or their partners \[[@ref3], [@ref4], [@ref5]\] and furthermore whose incidence clearly disproportionately impacts women from the poorest social strata, and the most economically disadvantaged regions \[[@ref6]\]; to the extent that mortality rates from this cancer are three times higher in Latin America and the Caribbean than in the United States and Canada \[[@ref2]\].

The variations between countries in the region, for the period from 2000 to 2012, taken from the GLOBOCAN reports \[[@ref7]\], show a difference in the rates, standardised per 100,000 women, of up to five times the incidence (Puerto Rico 9.73 v Bolivia 50.73) and almost seven times the mortality (Puerto Rico 3.3 v Nicaragua 21.67). These differences are more strongly linked to unequal access to control measures than as a consequence of differences in the sexual conduct of the populations.

Descriptive aspects of cervical cancer in Latin America
=======================================================

It is useful to draw comparisons with data on the global incidence of cervical cancer. [Figures 1](#figure1){ref-type="fig"} and [2](#figure2){ref-type="fig"} show the specific distribution, which has led to the development of cervical cancer known as third most common cancer worldwide. Economically better off regions clearly show lower rates, with notable exceptions in North Africa, the Arabian Peninsula, and some near Asian areas, which while they are not part of the most economically developed areas of the world, show low rates, possibly due to the up keep of religious mores favouring conservative sexual conduct; a similar observation was presented by Drain *et al* in a work analysing determinants of cervical cancer rates in underdeveloped countries \[[@ref8]\].

In Latin America, cervical cancer puts an enormous strain on the health system \[[@ref2]\], presenting as the third most common cause of female cancer death, second only to lung and breast cancer; although in some countries, such as Honduras, Nicaragua, El Salvador, Bolivia, Paraguay, and Ecuador, it remains the principal cause of female cancer deaths. Nonetheless, it is one of the most preventable and curable forms of cancer, as shown by cancer statistics from developed countries.

In Latin America for 2012, almost 70,000 cases and 28,000 deaths from cervical cancer occurred, according to information compiled from GLOBOCAN data \[[@ref7]\].

The Pan American Health Organisation estimate for 2012 was around 36,000 deaths from this type of cancer across America with 80% of these deaths relating to Latin America and the Caribbean [www.paho.org/cancer/cervicalcancer](www.paho.org/cancer/cervicalcancer) \[[@ref9]\].

The descriptive epidemiological method is a valuable tool when referring to the social behaviour of disease, especially in relation to chronological trends, geographical distribution or individual factors.

This article is limited to those basically descriptive aspects of the epidemiology of cervical cancer in Latin America, as well as to understand its natural history and the evaluation of screening procedures and the possible impact of the vaccine against human papillomavirus (HPV), as a contribution to the understanding and control of the disease.

Evaluation of chronological trends and geographical distribution of cervical cancer, observed between 2000 and 2012, shows a reduction in mortality in absolute terms, from 31,000 deaths in 2000 to 28,000 in 2012 \[[@ref7]\]. This trend is obviously not proportionally distributed, and while in the majority of countries, there has been a reduction in mortality, but mortality rate increases in some countries.

To better appreciate the real variation in risk, we measure it using one indicator, such as the standardised rate, which takes into account the population structure by age group and as a benchmark, the adjusted Segi world standard population.

[Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"} and [Figures 3](#figure3){ref-type="fig"}, [4](#figure4){ref-type="fig"}, and [5](#figure5){ref-type="fig"} show trends in the incidence and mortality by country for the given period from 2000 to 2012, corresponding to cuts in 2000, 2008, and 2012; taken from GLOBOCAN data \[[@ref7]\]. [Table 2](#table2){ref-type="table"}, which relates to mortality, shows that rates in the majority of countries fell over the analysed period, with the exception of Bolivia, which showed a significant increase, Ecuador with a slight increase and Argentina and Uruguay while they have a low incidence showed a small increase in 2012, as can be seen in [Figures 4](#figure4){ref-type="fig"} and [5](#figure5){ref-type="fig"}.

The incidence of cervical cancer in Latin America shows a tendency over time very similar to mortality; a marked variation can be seen between countries in [Table 1](#table1){ref-type="table"} and [Figure 3](#figure3){ref-type="fig"}.

Individual factors include those variables linked to the personal characteristics of the women affected by the problem being studied. More than five decades of epidemiological evaluation has indisputably determined its relationship to the sexual habits of women and their partners; \[[@ref4]\] as well as other characteristics, which constitute the risk profile associated with the greater probability of this cancer presenting in certain women \[[@ref3]\].

A descriptive evaluation of the magnitude of the problem and its principal defining characteristics is shown below:

Magnitude of the problem
------------------------

Along with the data mentioned in previous paragraphs and supported by tables, quantifying the significant scale of the problem by incidence and mortality figures, it would be useful to use a different social and economic disease indicator. Over the past few decades, years of potential life lost have been used for this. However, their calculation requires access to information on the age distribution of women with cervical cancer across all Latin American countries, which is fairly difficult to obtain.

Other essential statistics are those relating to life expectancy among the female population in the countries analysed, which can be obtained from World Bank indicator reports \[[@ref10]\].

To avoid the stated difficulties, a mathematical model was applied based on the assessment carried out over the course of more than 20 years monitoring the behaviour of cervical cancer in Venezuela. This has shown a marked stability in indefinitely maintaining an average age of death of 55 years and a fairly stable percentage distribution by age group, as is shown in [Figures 6](#figure6){ref-type="fig"}, [7](#figure7){ref-type="fig"}, and [8](#figure8){ref-type="fig"}.

This allowed us to maintain the hypothesis, to be set out in a subsequent study, of similar behaviour in all other Latin American countries.

By applying the same percentage distribution by age at death for each country, it is assumed that the average age of death will equally be very close to 55 years. In our experience of analysing trends of mortality due to cervical cancer over a number of years, we have noticed that the average age is very close to the median in each annual series, which moreover have a pattern that approximates to a normal curve; consequently, taking the value of the average age at death and subtracting it from life expectancy would give us a value close to the average number of years of life lost by each death, and by multiplying this by the total number of deaths per period, we can estimate somewhat approximately the real number of years of life potentially lost, as shown in [Table 3](#table3){ref-type="table"}, which establishes for the region a loss of 633,000 potential years of life, especially in areas where the woman is the fundamental factor in a nuclear family.

Knowledge of distribution by age group is determined by the design of control strategies, meaning that its constant monitoring is needed for detecting possible variations over time.

As previously stated, in Venezuela, monitoring has been maintained, based on incidence rates by age group, expressed in classes spanning 5 years, which we have maintained since 1980.

Very similar curves have been observed, rising rapidly from class 20--24, up to 45--49, with the ascent slowing up to 55--59; beyond this point, the incidence rate begins to decrease.

[Figure 8](#figure8){ref-type="fig"} shows a comparison between the decades 1991--2000 and 2001--2006, during which periods a moderate decrease was seen in the rate of incidence, equally reflected across all age groups.

Therefore, this renders questionable the frequent affirmation by clinical specialists pointing to an increase in cases in younger women, which is simply an effect of population (larger current population in this age group means more cases, but not an increased risk, and still less a change in the natural history of this pathology).

As we have already shown, the average age of the cases and of death has remained stable in Venezuela ([Figure 6](#figure6){ref-type="fig"}) and there is a substantial enough basis for the stability of the natural history of this cancer \[[@ref11]\] to suppose that the same must be happening in the rest of Latin America.

Demographic factors include illiteracy, poverty and poor hygiene practices, little access to health services or attention to investigatory programmes based on periodical smear testing. These factors are consistently linked to higher incidences of, and mortality due to, cervical cancer, from which comes the connotation that it is a third world cancer, or the view that a high mortality rate from cervical cancer is an indicator of underdevelopment, but it is certain that the impacts of these factors are given in determining the influence of risky sexual habits and the lack of timely and appropriate access to prevent and control measures.

Other factors, such as smoking habits, are indicated in various studies to be tied to an increased risk of cervical cancer, linked to a doubling of risk to women smokers and correlating positively to the greater intensity and duration of the habit \[[@ref12]\]. The discovery of nicotine and the derivatives of tobacco smoke in cervical mucus, signalled by Schiffman, \[[@ref13]\] suggest a possible biological mechanism through immune-suppression, which encourages infection by the HPV.

Nutritional deficiency is a risk factor which has been closely evaluated, especially in relation to its potential application in chemoprevention. Evidence based on epidemiological studies exists showing that nutritional deficiency, in particular in vitamins A and C, lead to increased risk of cervical cancer. In one International Agency for Research on Cancer (IARC) study, high- and low-risk regions are compared, and a decreased risk is shown in areas with increased consumption of vitamin C and beta carotene \[[@ref14]\]. Other studies in Italy and the USA support these results \[[@ref15]\].

A multicentre study of cases and controls did not find any relationship between increased risk and levels of carotenoids, vitamin A or vitamin C, measured through information on the consumption of 75 types of foods \[[@ref16]\].

Over the course of many years, cervical cancer has been linked with sexual and reproductive factors. The first antecedents date from the observations of Doménico Rigoni-Stern in 1842 \[[@ref17]\] who described his discoveries in a statistical investigation across a number of decades of cancer mortality in the population of the Verona region of Italy, which showed the absence of cervical cancer in nuns, and a greater incidence in married or widowed women than among single women; this was followed almost a century later by the publication of similar discoveries by Lebian Gagnon \[[@ref18]\] in Quebec.

However, from the 1960 onwards, numerous works were published, many of which were included in the systematic revision by I D Rotkin \[[@ref19]\] in 1973, aiming to identify an infectious agent which, by transmission through sexual contact, could be the cause of this type of cancer.

It was Harald Zur Hausen \[[@ref20]\] who in 1983 identified the DNA of the HPV in the cancer cells in the cervix and subsequently with the epidemiological work of Nubia Muñoz, Xavier Bosh and Cols, \[[@ref21]\] the hypothesis was confirmed, that is, that the persistent infection with types 16, 18, 58, 31, etc. of the HPV, constituted the necessary factor, although not sufficient for the development of this malignancy.

Acceptance of HPV as a necessary factor in the development of cervical cancer lends value to the description of other sexual factors that could play a complementary role; these include initiation of sexual activity at a young age, which could be characterised as being under 18 years old, and risky sexual habits, defined as having more than two partners over the course of a sexually active life, with whom the relationship lasted not less than three months, or similar sexual habits in the male partner.

The increased risk posed by initiation of sexual activity at a young age is attributable to immunological immaturity of the cervical epithelium which allows for a viral infection and not as a factor in itself.

Risky sexual habits are directly linked to the possibility of infection by one or a number of the high-risk forms of HPV. The particular distribution of cervical cancer in certain regions of the world, which show the very low levels of mortality associated with restrictive sexual habits, consistently reinforces the role of sexual factors.

New Guinea is one of the examples that can support this hypothesis. It is an island located to the north of Australia, whose western portion belongs to Indonesia, and hence, the majority of the population are practising Muslims and mortality rates are much lower than the eastern part, Papua New Guinea ([Figure 1](#figure1){ref-type="fig"}), an independent country where only a minority of the population belong to this religion; thus highlighting variations in sexual habits as the cause of the marked difference.

The natural history of cervical cancer has been recognised in the last four to five decades, without there have been major changes beyond differences in the nomenclature of precancerous lesions or the identification of the HPV as the necessary agent, but not sufficiently to have developed and evolved into a malignant neoplasm. The importance of understanding the natural history of this pathology is in its application to control measures. As can be shown in [Table 4](#table4){ref-type="table"}, pre-cancerous lesions can be detected 5 to 10 years before women become clinically symptomatic \[[@ref11]\], thus identifying these lesions gives a good chance of arresting the development of the pathology.

Early detection monitoring procedures for cervical cancer or its precursor lesions have been in place for some time, ever since the early development of the Aurel Babes and George Papanicolou cervicovaginal cytology technique \[[@ref22]\] and colposcopy developed by Hans Heinselman \[[@ref23]\].

Cervicovaginal cytology has had a significant impact on the control of this disease, despite having numerous detractors. However, it is not a simple method, as in order to be effective, it requires a well-structured organisation, supported by a population-based programme and a health system with well-defined levels, with complete decentralisation of the regular collection of cytology samples at clearly defined intervals, and with a protocol based on the epidemiological knowledge and potential of the cytology method. It requires well-equipped cytopathology laboratories, capable of processing no fewer than 40,000 smears annually, with strict quality controls and sufficiently qualified staff; and it also needs clinics for referring cases (Cervical Pathology Clinic), located strategically and with trained staff, able to promptly assess and treat (if necessary) all cases identified by cytological testing, who must have been located, given an appointment and treated appropriately, according to the programme protocol.

It is evident from the above that it is not a simple method, and it is also clear that it can operate with good results on an "opportunistic" basis, as in the USA, but this is only possible in countries with a high income per inhabitant, with costs that are multiples of those of scheduled, population-based research, as has been demonstrated in Scandinavia, Great Britain and many regions of France, Italy or Germany \[[@ref24]\].

Appropriate, regular, well-structured access to cytology has been the main factor in determining the difference between countries at high risk and those at intermediate or lower risk ([Table 5](#table5){ref-type="table"}). The knowledge, though limited, obtained from Pan American Health Organisation (PAHO) reports \[[@ref25], [@ref26]\] on the percentage of cytology cover in Latin American countries fits fairly precisely inside the epidemiological profile of countries at low risk with mortality rates below 10, countries at intermediate risk with rates of 10 to 15, and countries at high risk, above 15. Some countries do not report on their cytology cover, such as Puerto Rico, but this should be close to the average for the USA which is 80%. Others, such as Venezuela or Panamá, report only cover corresponding to the Ministry of Health, and the percentage should therefore be around 50%. This correlation, which provides a fairly good match between good rates of cytology cover and low mortality rates and vice versa, is why we have accepted that the most decisive risk factor in mortality due to cervical cancer is the absence of appropriate cytological testing.

Other detection methods, such as direct visualisation of the cervix with acetic acid (visual inspection with acetic acid: VIAA) or with iodine (visual inspection with Lugol's iodine: VILI) carried out by nurses or trained technicians, have gained importance in recent years, and these may be an option in rural populations with an under-developed health system \[[@ref27]\]. With the advent of molecular biology techniques applied clinically for the diagnosis of high-risk types of HPV, which offer promising prospects in the more efficient detection of high-grade intraepithelial lesions \[[@ref28]\], and which are gaining ground as costs are falling, and which offer a greater potential for large-scale use, we will thus have tools that facilitate monitoring and reduce the huge health and socioeconomic burden represented by cervical cancer in Latin America.

Vaccines against HPV
====================

With the approval in 2006 of two vaccines against the high-risk HPV types 16 and 18 (which are present in 70% of carcinomas of the cervix) and their potential to reach types 31, 33, and 45 by cross immunity (which would provide approximately 10% additional protection), a powerful weapon is available for preventing approximately 85% of the risk of contracting cervical cancer in the coming years \[[@ref29]\].

The majority of Latin American countries have begun HPV vaccination in recent years, but there is insufficient information available on the rates of cover achieved. Although appropriate vaccination levels have been reached, the impact of the effectiveness of the vaccine in preventing cervical cancer will not be observed for about 20 years. Screening procedures with the methods and adaptations specific to each region should therefore be maintained, along with efficient vaccination cover, to achieve effective control of cervical cancer in coming decades.

In an empirical mathematical model, which we use to measure the long-term impact of vaccination in Venezuela and on the premise that the current mortality rate remains stable or shows a slight downward trend, results would begin to be observed from the next 15 years onwards and the greatest impact would be achieved in about 30 years, as shown in [Figures 9](#figure9){ref-type="fig"} and [10](#figure10){ref-type="fig"}, which show a reduction of approximately 50,000 cases between 2030 and 2060, with a percentage reduction of 30.7%; a rapid fall in the number of cases should occur from 2060.

Conclusion
==========

Cervical cancer has affected the human race for millennia and has wreaked havoc owing to its social and economic scale and impact, particularly in the disadvantaged regions of the world. The fight to control it has been slow; however, it is a clear example of how the development of medical knowledge in diagnosis, therapy, and prevention is paying off in terms of health.

The advent of vaccines to prevent infection by HPV types 16 and 18, which in worldwide studies have proved to be linked to 70% of the risk of suffering invasive cervical cancer and appear to have cross immunity for types 31, 33, and 45, as well as new research prospects involving low-cost procedures and potential widespread application for the detection of HPV risk types, suggest that the fight against cervical cancer is on the way to being won and that this achievement will undoubtedly have a key role in epidemiology.
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###### Incidence of cervical cancer in America 2000, 2008, and 2012.

  Countries            Incidence 2000   Incidence 2008   Incidence 2012   Mean Standard Rate 2000--2012                  
  -------------------- ---------------- ---------------- ---------------- ------------------------------- ------- ------ -------
  Argentina            2953             14.2             3996             17.5                            4956    20.9   17.53
  Bolivia              1807             58.1             1442             46.4                            2029    47.7   50.73
  Brazil               24445            31.3             24562            24.5                            18503   16.3   24.03
  Chile                2321             29.2             1478             14.4                            1441    12.8   18.80
  Colombia             5901             32.9             4176             21.5                            4661    18.7   24.37
  Costa Rica           424              25               403              17.5                            297     11.4   17.97
  Cuba                 1586             23.8             1603             23.1                            1287    17.1   21.33
  Ecuador              2231             44.2             1666             27.1                            2094    29.0   33.43
  El Salvador          1041             40.6             1145             37.2                            823     24.8   34.20
  Guatemala            1432             39.6             1530             30.5                            1393    22.3   30.80
  Honduras             833              39.6             1014             37.8                            991     29.4   35.60
  Jamaica              489              43.4             624              45.7                            392     26.3   38.47
  Mexico               16448            40.5             10186            19.2                            13960   23.3   27.67
  Nicaragua            997              61.1             869              39.9                            934     36.2   45.73
  Panama               389              31.2             426              25.3                            351     18.7   25.07
  Paraguay             768              41.1             864              35                              1022    34.2   36.77
  Peru                 4101             39.9             3445             34.6                            4636    32.7   35.73
  Puerto Rico          252              10.3             209              7.5                             259     11.4   9.73
  Dominican Republic   1290             38.4             1299             29.7                            1507    30.7   32.93
  Uruguay              307              13.8             348              16.5                            402     19.0   16.43
  Venezuela            3904             38.3             4116             31.4                            4973    32.8   34.17

Standardised rates per 100,000 women according to the world population model

**Source:** GLOBOCAN (2000, 2008, 2012).

###### Mortality due to cervical cancer Latin America (2000, 2008, 2012).

  Countries            Mortality 2000   Mortality 2008   Mortality 2012                  
  -------------------- ---------------- ---------------- ---------------- ------ ------- ------
  Argentina            1585             7.6              1809             7.4    2127    8.4
  Bolivia              661              22.2             638              16.7   845     21.0
  Brazil               8815             11.6             11055            10.9   8414    7.3
  Chile                860              10.6             721              6.6    734     6.0
  Colombia             2339             13.7             2154             10     1986    8.0
  Costa Rica           197              12.1             158              6.7    116     4.4
  Cuba                 730              10.6             684              8.9    569     6.7
  Ecuador              892              18.6             832              13.3   1,026   14.0
  El Salvador          387              15.8             563              18.2   388     11.9
  Guatemala            566              16.8             717              5.2    672     12.2
  Haiti                1326             53.5             353              10.1   575     14.6
  Honduras             329              16.8             490              19.7   417     14.1
  Mexico               6650             17.1             5061             9.7    4769    8.1
  Nicaragua            392              26.1             414              20.6   424     18.3
  Panama               158              13.1             211              12.6   134     7.1
  Paraguay             281              15.8             407              16.6   439     15.7
  Peru                 1575             15.8             2098             16.3   1715    12.0
  Puerto Rico          114              4.3              89               2.8    84      2.8
  Dominican Republic   495              15.8             591              13.7   600     12.3
  Uruguay              163              7.6              159              6.8    175     7.1
  Venezuela            1454             15.2             1853             14.4   1789    12.3
  Total                29969            12.8             31057            10.7   27998   8.6

Standardised rates per 100,000 women according to the world population model

**Source:** GLOBOCAN (2000, 2008, 2012).

###### Cervical cancer in Latin America. Potential years of life lost in 2012.

  Countries            Number of deaths   Life expectancy (LE)   Potential years of life lost (PYLL)
  -------------------- ------------------ ---------------------- -------------------------------------
  Argentina            2127               80                     53175
  Bolivia              845                69                     11830
  Brazil               8414               77                     185, 108
  Chile                734                82                     19818
  Colombia             1986               78                     45678
  Costa Rica           116                82                     3132
  Cuba                 569                81                     14794
  Ecuador              1026               79                     24624
  El Salvador          388                77                     8536
  Guatemala            672                75                     13440
  Haiti                575                65                     5750
  Honduras             417                76                     8757
  Mexico               4769               80                     119, 225
  Nicaragua            424                78                     9752
  Panama               134                80                     3350
  Paraguay             439                74                     8341
  Peru                 1715               77                     37730
  Puerto Rico          84                 82                     2268
  Dominican Republic   600                76                     12600
  Uruguay              175                80                     4375
  Venezuela            1789               78                     41147
  Total                27998                                     633, 430

**Source:** Deaths, according to GLOBOCAN 2012.

LE: [www.bancomundial.org/datos/indicador/SP.DYN%20LE00.FE.IN](www.bancomundial.org/datos/indicador/SP.DYN%20LE00.FE.IN)

PYLL: Estimates according to a mathematical model

###### Cervical cancer. Natural history.

  Asymptomatic period   Symptomatic period                                                                               
  --------------------- -------------------------------------------------- --------------------------------------------- ---------------------------
  Susceptible women     Action of risk factors                             Preneoplastic stage                           Neoplastic stage
  Progression           Period from 5 to 20 years                          Period from 5 to 15 years                     Period from 3 to 10 years
  Course of disease     Infection with high-risk HPV and other cofactors   Low- and high-grade intraepithelial lesions   Invasive cancer
  Age ranges            Women aged 15 to 40 years                          Women aged 20 to 60 years                     Women aged 20 to 65 years

**Source:** GLOBOCAN (2000, 2008, 2012) and cancer in the country profiles America 2013.

Cytological cover: Cancer in the Americas: Country Profiles 2013, Washington, DC

###### Cervical cancer in Latin America. Correlation between mean mortality rate and cytological cover (2000, 2008, 2012).

  Countries            Mortality   Cytological cover                  
  -------------------- ----------- ------------------- ------ ------- -------
  Puerto Rico          4.3         2.8                 2.8    3.30    ?
  Uruguay              7.6         6.8                 7.1    7.17    55.20
  Chile                10.6        6.6                 6      7.73    60.00
  Costa Rica           12.1        6.7                 4.4    7.73    35.00
  Argentina            7.6         7.4                 8.4    7.80    60.00
  Cuba                 10.6        8.9                 6.7    8.73    70.00
  Brazil               11.6        10.9                7.3    9.93    79.30
  Colombia             13.7        10                  8      10.57   79.00
  Panama               13.1        12.6                7.1    10.93   14.10
  Mexico               17.1        9.7                 8.1    11.63   70.70
  Dominican Republic   15.8        13.7                12.3   13.93   ?
  Venezuela            15.2        14.4                12.3   13.97   25.00
  Peru                 15.8        16.3                12     14.70   51.30
  Guatemala            16.8        15.2                12.2   14.73   ?
  El Salvador          15.8        18.2                11.9   15.30   17.80
  Ecuador              18.6        13.3                14     15.30   64.30
  Paraguay             15.8        16.6                15.7   16.03   ?
  Honduras             16.8        19.7                14.1   16.87   41.80
  Bolivia              22.2        16.7                21     19.97   12.00
  Nicaragua            26.1        20.6                18.3   21.67   10.00

Standardised rates per 100,000 women according to the world population model

**Source:** GLOBOCAN (2000, 2008, 2012) and cancer in the America country profiles 2013.a
